Clinical trials: Philadelphia-Positive ALL
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027924
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells.
- Trial name
- NCT00003239
- Testing
- Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
B Acute Lymphoblastic Leukemia
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia…
- Trial name
- NCT06124157
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy
- Where
- 161 sites in United States, Australia and 2 more
- Volunteers
- 222 people
- Sponsor
- National Cancer Institute (NCI)
Myelogenous Leukemia, Chronic, Chronic Phase
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
The goal of this clinical research study is to see if higher doses of imatinib mesylate (Gleevec, STI571) can improve chronic myelogenous leukemia (CML) in chronic phase.
- Trial name
- NCT00038649
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of interferon alfa may be as effective as high doses.
- Trial name
- NCT00002869
- Testing
- recombinant interferon alfa, cytarabine, hydroxyurea
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Medical Research Council
Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.
- Trial name
- NCT01221376
- Testing
- Imatinib Mesylate
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Renato Melaragno
Leukemia
Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00119340
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Fred Hutchinson Cancer Center
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia
Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00618501
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Asan Medical Center
Acute Lymphoblastic Leukemia
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02010931
- Where
- 10 sites in Czechia, France and 6 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in…
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
- Trial name
- NCT05495035
- Testing
- Olverembatinib, APG-2575, Dexamethasone
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
- Trial name
- DIALOG (NCT01844765)
- Testing
- nilotinib
- Where
- 36 sites in United States, France and 11 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, Cromosome Philadelphia Positive
Glivec in Ph Positive Lymphoblastic Leukemia
% positive Ph LLA with RC alter the Glivec and induction chemotherapy treatment
- Trial name
- NCT00388895
- Testing
- chemotherapy, Glivec
- Where
- 28 sites in Spain
- Volunteers
- 35 people
- Sponsor
- PETHEMA Foundation
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia-Negative ALL, Philadelphia-Positive ALL
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the…
- Conditions
- Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT06287528
- Testing
- 19-28z/IL-18 CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia…
- Trial name
- NCT00004933
- Testing
- hydroxyurea, Homoharringtonine
- Where
- 133 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
Primary Objective: 1. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+) CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell transplantation.
- Trial name
- NCT00386373
- Testing
- Imatinib Mesylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.
- Trial name
- NCT00130195
- Testing
- imatinib, cyclophosphamide, daunorubicin
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Japan Adult Leukemia Study Group
Leukemia, Pediatric
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
- Trial name
- NCT01460160
- Testing
- Dasatinib
- Where
- 128 sites in United States, Australia and 4 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb